Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
 BACK TO LIST

European Patient Summary

Patient
Name: Taylor, , Eileen,
DOB: 11-DEC-1951 (Age: 73)
Gender: female
ID: 6172-576075-7 (ECI)
Author
Dr. Ping, Hel
Patient summary Document
European Patient Summary
Report Date: 05-MAY-2025

Problem list

Condition Onset Date Status
Fibromyalgia 05-Feb-2014 active
Osteoarthritis of knee 19-Mar-2008 active
Hyperlipidemia 23-Dec-1996 active
Malignant neoplasm of breast 05-May-1988 active
Recurrent urinary tract infection 14-May-1973 active

Medication list

Medication Since Form Dosage Reason
Simvastatin 10 mg oral tablet 2025-05-05 - 1 tablet (10 mg) by mouth once daily Hyperlipidemia
Naproxen sodium 220 mg oral capsule 2008-03-19 - 1 capsule (220 mg) by mouth every 12 hours as needed Osteoarthritis of knee

Immunizations list

Vaccine Date
Influenza virus antigen only vaccine product 28-Apr-2025
SARS-CoV-2 mRNA vaccine 22-Feb-2021
Clostridium tetani toxoid antigen adsorbed only vaccine product 30-Mar-2020

Procedure History list

Procedure Date Reason
Suture open wound 20-Jun-2024 Facial laceration
Injection of tetanus antitoxin 20-Jun-2024 Facial laceration
Patient discharge 17-Dec-2023 -
Hospice care 16-Dec-2023 -
Notifications 04-Dec-2023 -
Certification procedure 04-Dec-2023 -
Initial patient assessment 04-Dec-2023 -
Development of individualized plan of care 04-Dec-2023 -

Allergies and Intolerances

Allergy/Intolerance Onset Date Status Type Reaction
? active ?

Care Plan

Active Planned Care / Goals Start Date Reason
Musculoskeletal care 19-Mar-2008 Osteoarthritis of knee
  • Reduce knee pain severity to a tolerable level to improve mobility and quality of life
  • Increase ability to walk and perform daily activities without significant limitation from knee osteoarthritis
  • Engage in at least 30 minutes of moderate physical activity most days of the week as tolerated
Hyperlipidemia clinical management plan 13-Jan-1997 Hyperlipidemia
  • Achieve and maintain LDL cholesterol below 2.6 mmol/L
  • Achieve and maintain total cholesterol below 5.2 mmol/L
  • Maintain HDL cholesterol above 1.3 mmol/L
  • Achieve and maintain triglycerides below 1.7 mmol/L
Immunization Recommendation Due Date Reason
Vaccine product containing only Influenza virus antigen (medicinal product) 01-Oct-2025 Annual seasonal influenza vaccination

Vital Signs

Vital Signs 2025-04-28 2024-04-22
Body Height 155 cm 155 cm
Pain severity - 0-10 verbal numeric rating [Score] - Reported 3 {score} 2 {score}
Body Weight 67.1 kg 67.1 kg
Body mass index (BMI) [Ratio] 27.9 kg/m2 27.9 kg/m2
Diastolic Blood Pressure 82 mm[Hg] 82 mm[Hg]
Systolic Blood Pressure 125 mm[Hg] 123 mm[Hg]
Heart rate 86 /min 67 /min
Respiratory rate 16 /min 12 /min

Relevant diagnostic tests/laboratory data

Recent Lab Observations 05-MAY-2025 Reference Range Unit
Glucose [Mass/volume] in Blood 99.4 70 - 140 mg/dL
Urea nitrogen [Mass/volume] in Blood 15.8 7 - 20 mg/dL
Creatinine [Mass/volume] in Blood 3.1 H 0.6 - 1.1 mg/dL
Calcium [Mass/volume] in Blood 9.7 8.5 - 10.4 mg/dL
Sodium [Moles/volume] in Blood 136.4 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.5 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Blood 105.1 98 - 108 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 26.1 22 - 29 mmol/L
Protein [Mass/volume] in Serum or Plasma 6.8 6 - 8.3 g/dL
Albumin [Mass/volume] in Serum or Plasma 5.2 H 3.4 - 5 g/dL
Globulin [Mass/volume] in Serum by calculation 2.1 2 - 3.5 g/L
Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 0.2 - 1.2 mg/dL
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 127.5 H 44 - 104 U/L
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 46.3 H 13 - 36 U/L
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 36.8 10 - 40 U/L
Cholesterol [Mass/volume] in Serum or Plasma 181.1 130 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 101.8 35 - 175 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 94.0 0 - 190 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 54.9 50 - 100 mg/dL

Device Use

Device Date (since)
Wheelchair accessory (physical object) 19-Mar-2008
Power-assisted wheelchair (physical object) 19-Mar-2008